论文部分内容阅读
目的观察吡柔比星联合阿糖胞苷治疗难治性急性髓细胞白血病的临床疗效,探索难治性急性髓细胞白血病较为可靠的有效治疗方法。方法26例患者均应用吡柔比星联合阿糖胞苷化疗,5～7天为一疗程,二个疗程评价疗效。结果26例患者完全缓解(CR)10例,CR率38.5%;部分缓解(PR)7例,PR率26.9%;未缓解(NR)9例,总有效率65.4%。毒副作用主要为骨髓抑制,未发现明显心脏、肝脏功能损伤。结论吡柔比星联合阿糖胞苷为治疗难治性急性髓细胞白血病疗效可靠的方案,除骨髓抑制外,未发现其它明显毒副反应。
Objective To observe the clinical efficacy of pirarubicin combined with cytarabine in the treatment of refractory acute myeloid leukemia and to explore a more reliable and effective treatment for refractory acute myeloid leukemia. Methods 26 patients were treated with pirarubicin combined with cytarabine chemotherapy, 5 to 7 days for a course of treatment, evaluation of two courses of treatment. Results The complete remission (CR) rate was 10 in 26 patients. The CR rate was 38.5%. The partial response (PR) was 7 and the PR rate was 26.9%. In 9 patients without remission (NR), the total effective rate was 65.4%. The main side effects of bone marrow suppression, no significant heart, liver function damage. Conclusion Pirarubicin combined with cytarabine in the treatment of refractory acute myeloid leukemia, a reliable program, in addition to bone marrow suppression, and found no other obvious side effects.